344 related articles for article (PubMed ID: 12365204)
41. Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance.
Zhang L; Beal SL; Sheiner LB
J Pharmacokinet Pharmacodyn; 2003 Dec; 30(6):387-404. PubMed ID: 15000421
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of population (NONMEM) pharmacokinetic parameter estimates.
Vozeh S; Maitre PO; Stanski DR
J Pharmacokinet Biopharm; 1990 Apr; 18(2):161-73. PubMed ID: 2348382
[TBL] [Abstract][Full Text] [Related]
43. Comparison of stepwise and simultaneous estimations of population pharmacokinetics and pharmacodynamics of TS-943.
Furuya A; Kato N; Jingu S; Akimoto M; Kasai O; Suwa T; Sato M; Ogata H
Eur J Drug Metab Pharmacokinet; 2003; 28(3):191-9. PubMed ID: 14527092
[TBL] [Abstract][Full Text] [Related]
44. Population pharmacokinetic investigation of actinomycin-D in children and young adults.
Mondick JT; Gibiansky L; Gastonguay MR; Skolnik JM; Cole M; Veal GJ; Boddy AV; Adamson PC; Barrett JS
J Clin Pharmacol; 2008 Jan; 48(1):35-42. PubMed ID: 18094218
[TBL] [Abstract][Full Text] [Related]
45. dOFV distributions: a new diagnostic for the adequacy of parameter uncertainty in nonlinear mixed-effects models applied to the bootstrap.
Dosne AG; Niebecker R; Karlsson MO
J Pharmacokinet Pharmacodyn; 2016 Dec; 43(6):597-608. PubMed ID: 27730481
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data.
Sheiner LB; Beal SL
J Pharmacokinet Biopharm; 1980 Dec; 8(6):553-71. PubMed ID: 7229908
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of bootstrap methods for estimating uncertainty of parameters in nonlinear mixed-effects models: a simulation study in population pharmacokinetics.
Thai HT; Mentré F; Holford NH; Veyrat-Follet C; Comets E
J Pharmacokinet Pharmacodyn; 2014 Feb; 41(1):15-33. PubMed ID: 24317870
[TBL] [Abstract][Full Text] [Related]
48. Prior information for population pharmacokinetic and pharmacokinetic/pharmacodynamic analysis: overview and guidance with a focus on the NONMEM PRIOR subroutine.
Chan Kwong AHP; Calvier EAM; Fabre D; Gattacceca F; Khier S
J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):431-446. PubMed ID: 32535847
[TBL] [Abstract][Full Text] [Related]
49. Pharmacokinetic Studies in Neonates: The Utility of an Opportunistic Sampling Design.
Leroux S; Turner MA; Guellec CB; Hill H; van den Anker JN; Kearns GL; Jacqz-Aigrain E; Zhao W;
Clin Pharmacokinet; 2015 Dec; 54(12):1273-85. PubMed ID: 26063050
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of the nonparametric estimation method in NONMEM VI.
Savic RM; Kjellsson MC; Karlsson MO
Eur J Pharm Sci; 2009 Apr; 37(1):27-35. PubMed ID: 19159684
[TBL] [Abstract][Full Text] [Related]
51. Population pharmacokinetics of mycophenolic acid in pediatric renal transplant patients using parametric and nonparametric approaches.
Prémaud A; Weber LT; Tönshoff B; Armstrong VW; Oellerich M; Urien S; Marquet P; Rousseau A
Pharmacol Res; 2011 Mar; 63(3):216-24. PubMed ID: 21056671
[TBL] [Abstract][Full Text] [Related]
52. The use of bootstrap methods for estimating sample size and analysing health-related quality of life outcomes.
Walters SJ; Campbell MJ
Stat Med; 2005 Apr; 24(7):1075-102. PubMed ID: 15570625
[TBL] [Abstract][Full Text] [Related]
53. Evaluation of the nonparametric estimation method in NONMEM VI: application to real data.
Baverel PG; Savic RM; Wilkins JJ; Karlsson MO
J Pharmacokinet Pharmacodyn; 2009 Aug; 36(4):297-315. PubMed ID: 19572188
[TBL] [Abstract][Full Text] [Related]
54. Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation.
Van Kesteren Ch; Mathôt RA; Raymond E; Armand JP; Dittrich Ch; Dumez H; Roché H; Droz JP; Punt C; Ravic M; Wanders J; Beijnen JH; Fumoleau P; Schellens JH;
J Clin Oncol; 2002 Oct; 20(19):4065-73. PubMed ID: 12351604
[TBL] [Abstract][Full Text] [Related]
55. Standard errors in covariance structure models: asymptotics versus bootstrap.
Yuan KH; Hayashi K
Br J Math Stat Psychol; 2006 Nov; 59(Pt 2):397-417. PubMed ID: 17067418
[TBL] [Abstract][Full Text] [Related]
56. Sample size calculations based on generalized estimating equations for population pharmacokinetic experiments.
Ogungbenro K; Aarons L; Graham G
J Biopharm Stat; 2006; 16(2):135-50. PubMed ID: 16584063
[TBL] [Abstract][Full Text] [Related]
57. Using SAS to conduct nonparametric residual bootstrap multilevel modeling with a small number of groups.
Wang J; Carpenter JR; Kepler MA
Comput Methods Programs Biomed; 2006 May; 82(2):130-43. PubMed ID: 16569459
[TBL] [Abstract][Full Text] [Related]
58. Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM.
Jonsson EN; Karlsson MO
Comput Methods Programs Biomed; 1999 Jan; 58(1):51-64. PubMed ID: 10195646
[TBL] [Abstract][Full Text] [Related]
59. A population pharmacokinetic model of valproic acid in pediatric patients with epilepsy: a non-linear pharmacokinetic model based on protein-binding saturation.
Ding J; Wang Y; Lin W; Wang C; Zhao L; Li X; Zhao Z; Miao L; Jiao Z
Clin Pharmacokinet; 2015 Mar; 54(3):305-17. PubMed ID: 25388986
[TBL] [Abstract][Full Text] [Related]
60. Assessing the uncertainty in QUANTEC's dose-response relation of lung and spinal cord with a bootstrap analysis.
Wedenberg M
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):795-801. PubMed ID: 23953634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
